Antibodies positive for P.1 variants in LTC residents

Published Date: 16 Feb 2023

How is the SARS-CoV-2 mRNA antibody similar to the P.1 gamma strain and other strains?

Read Full News

Todays Updates


Understanding the Long-Term Effects of Traumatic Brain Injury in Military Personnel: Clayton Mucha, MD Louie Pasculli, Clayton Mucha, MD


In honor of Veterans Day, Clayton Mucha, DO, neurorehabilitation physiatrist at Burke Rehabilitation in New York, discusses the lasting effects of traumatic brain injury in military personnel.

GV101 Gains FDA Fast Track Status for Friedreich Ataxia Ahead of Phase 2 Trial Isabella Ciccone, MPH


GV101 receives FDA fast track designation for the treatment of Friedreich ataxia, with a phase 2 trial planned to begin enrollment in late 2026.

FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study Isabella Ciccone, MPH


The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.

Awareness, Not Access, Remains the Barrier to NF1 Therapy Marco Meglio


At a NeurologyLive Clinical Forum in Phoenix, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how NF1-associated plexiform neurofibromas get recognized, referred, and treated.

Headlining Current Advances and Challenges in Multiple Sclerosis Care Robert Bermel, MD, Louie Pasculli


Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.

Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care


Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care

Todays Updates


Understanding the Long-Term Effects of Traumatic Brain Injury in Military Personnel: Clayton Mucha, MD Louie Pasculli, Clayton Mucha, MD


In honor of Veterans Day, Clayton Mucha, DO, neurorehabilitation physiatrist at Burke Rehabilitation in New York, discusses the lasting effects of traumatic brain injury in military personnel.

GV101 Gains FDA Fast Track Status for Friedreich Ataxia Ahead of Phase 2 Trial Isabella Ciccone, MPH


GV101 receives FDA fast track designation for the treatment of Friedreich ataxia, with a phase 2 trial planned to begin enrollment in late 2026.

FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study Isabella Ciccone, MPH


The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.

Awareness, Not Access, Remains the Barrier to NF1 Therapy Marco Meglio


At a NeurologyLive Clinical Forum in Phoenix, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how NF1-associated plexiform neurofibromas get recognized, referred, and treated.

Headlining Current Advances and Challenges in Multiple Sclerosis Care Robert Bermel, MD, Louie Pasculli


Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.

Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care


Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In prostate cancer survivorship, sleep disturbances are underappreciated.

2.

Nanoparticle vaccine prevents multiple cancers and stops metastasis in mice

3.

Study confirms link between breast density, higher breast cancer risk

4.

Guideline on management of early-stage non-small cell lung cancer released

5.

Study: For predicting breast cancer, AI performs better than traditional risk models.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot